After positive midstage trial, GSK moves mRNA flu vaccine to late-stage trials
Written By : MD Bureau Team
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-09-13 09:26 GMT | Update On 2024-09-13 09:26 GMT
British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development.
The data showed that a vaccine candidate produced positive immune responses against both A and B flu strains in younger and older adults, compared with the current standard treatments, GSK said.
In July, GSK bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials.
GSK, one of the world's largest vaccine manufacturers, under CEO Emma Walmsley has focussed on vaccines and infectious diseases as a strategy to boost sales and counter patent expiries and declining revenue from current bestselling medicines by the end of this decade.
"GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing," it said in a statement.
The trial tested various mRNA formulations in older and younger adults to find effective vaccines that could offer better protection against flu strains than current vaccines.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.